Skip to main
NRSN

NRSN Stock Forecast & Price Target

NRSN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeuroSense Therapeutics is effectively advancing its development pipeline for PrimeC, demonstrating a significant 29.2% slowing of disease progression in ALS patients during its Phase 2b PARADIGM study, which aligns with favorable reported safety and tolerability outcomes. The potential regulatory approval in Canada by 2026 is expected to enhance opportunities for regional commercial partnerships, providing avenues for non-dilutive capital. With continued regulatory progress and positive clinical results, the likelihood of strategic partnerships in North America and Europe is increasing, signaling a robust outlook for the company's future prospects.

Bears say

The financial outlook for NeuroSense Therapeutics appears negative, primarily due to concerns over dwindling cash reserves, which may necessitate a capital raise. This potential need for additional financing could dilute existing shareholders' equity and create uncertainty regarding the company's financial stability. Moreover, the reliance on the commercial success of its lead product candidate, PrimeC, amidst a competitive biotechnology landscape further complicates its revenue prospects.

NRSN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroSense Therapeutics Ltd (NRSN) Forecast

Analysts have given NRSN a Strong Buy based on their latest research and market trends.

According to 1 analysts, NRSN has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroSense Therapeutics Ltd (NRSN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.